Literature DB >> 19422463

Distinct C-terminus of the B subunit of factor XIII in a population-associated major phenotype: the first case of complete allele-specific alternative splicing products in the coagulation and fibrinolytic systems.

H Iwata1, T Kitano, K Umetsu, I Yuasa, K Yamazaki, B Kemkes-Matthes, A Ichinose.   

Abstract

OBJECTIVES: The purpose of this study was to elucidate the molecular bases of the heterogeneity of the B subunit of coagulation factor XIII (FXIII-B), classified by isoelectric focusing into its three population-associated major phenotypes. METHODS AND
RESULTS: By genetic sequencing and polymerase chain reaction (PCR)-restriction fragment length polymorphism analyses, a C-to-G change was identified in intron K for the Asian-associated major phenotype FXIII-B*3. A transcript containing the novel exon XII' was detected by reverse transcription PCR using hepatocyte cell lines with this allele. The exclusive existence of a novel C-terminal peptide in a homozygote of FXIII-B*3 was also detected by matrix-assisted laser-desorption ionization time of flight mass spectrometry. The FXIII-B*3 isoform had a C-terminus 15 residues longer than the other isoforms, containing two additional basic amino acids and one extra acidic amino acid. Accordingly, the C-to-G nucleotide substitution created an efficient splice acceptor AG dinucleotide, which resulted in allele-specific alternative splicing in intron K. When compared with FXIII-B*1, the third major phenotype, FXIII-B*2, had an A-to-G change in exon III, converting His95 to Arg, and a rare phenotype, FXIII-B*4, had an A-to-T change in exon VII, converting Glu368 to Val.
CONCLUSIONS: We found an extremely rare event of complete allele-specific alternative splicing for FXIII-B. The FXIII-B*3 isoform had a distinct C-terminal peptide, while the FXIII-B*2 and FXIII-B*4 isoforms had His95 to Arg and Glu368 to Val substitutions, respectively, which led to differential isoelectric points of these isoforms. Such variations in the amino acid sequence of FXIII-B may have profound effects on its structure-function relationship, plasma FXIII levels, and disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422463     DOI: 10.1111/j.1538-7836.2009.03443.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

2.  The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.

Authors:  Masayoshi Souri; Tsukasa Osaki; Akitada Ichinose
Journal:  J Biol Chem       Date:  2015-03-25       Impact factor: 5.157

Review 3.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

4.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

5.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

6.  Common FXIII and fibrinogen polymorphisms in abdominal aortic aneurysms.

Authors:  Fraser L Macrae; Hannah Lee Evans; Katherine I Bridge; Anne Johnson; D Julian A Scott; Robert A S Ariëns
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

Review 7.  Alu retrotransposons and COVID-19 susceptibility and morbidity.

Authors:  Manci Li; Luca Schifanella; Peter A Larsen
Journal:  Hum Genomics       Date:  2021-01-04       Impact factor: 4.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.